1. Home
  2. MSB vs NGNE Comparison

MSB vs NGNE Comparison

Compare MSB & NGNE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesabi Trust

MSB

Mesabi Trust

HOLD

Current Price

$23.93

Market Cap

334.0M

ML Signal

HOLD

Logo Neurogene Inc.

NGNE

Neurogene Inc.

HOLD

Current Price

$28.96

Market Cap

327.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
MSB
NGNE
Founded
1961
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
334.0M
327.8M
IPO Year
1995
2014

Fundamental Metrics

Financial Performance
Metric
MSB
NGNE
Price
$23.93
$28.96
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$63.57
AVG Volume (30 Days)
61.7K
116.6K
Earning Date
04-24-2026
05-08-2026
Dividend Yield
4.80%
N/A
EPS Growth
391.29
0.93
EPS
0.85
N/A
Revenue
$98,595,651.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$28.13
N/A
Revenue Growth
331.26
N/A
52 Week Low
$22.55
$14.65
52 Week High
$42.38
$37.27

Technical Indicators

Market Signals
Indicator
MSB
NGNE
Relative Strength Index (RSI) 31.22 55.94
Support Level N/A $28.37
Resistance Level $33.07 $28.93
Average True Range (ATR) 1.34 1.83
MACD -0.20 -0.09
Stochastic Oscillator 6.94 80.48

Price Performance

Historical Comparison
MSB
NGNE

About MSB Mesabi Trust

Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the northeastern end of the Mesabi Iron Range.

About NGNE Neurogene Inc.

Neurogene Inc is a clinical-stage biotechnology company committed to overcoming the limitations of neurological diseases into treatable conditions, by harnessing its proprietary transgene regulation technology, EXACTTM (Expression Attenuation via Construct Tuning). It is building a differentiated product portfolio of genetic medicines for rare neurological diseases with high unmet needs. The drug candidates in the company's product pipeline include NGN-401, which is in development for the treatment of Rett syndrome, using its EXACT platform, and NGN-101, a non-EXACT, conventional gene therapy development candidate for the treatment of CLN5 Batten disease, designed to deliver the CLN5 gene and packaged in an AAV9 capsid.

Share on Social Networks: